Share on StockTwits

Equities researchers at Leerink Swann initiated coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research report issued on Tuesday, reports. The firm set a “market perform” rating and a $23.50 price target on the stock. Leerink Swann’s price target would suggest a potential upside of 1.25% from the company’s current price.

T2 Biosystems (NASDAQ:TTOO) traded down 10.19% on Tuesday, hitting $20.844. The stock had a trading volume of 93,739 shares. T2 Biosystems has a one year low of $13.40 and a one year high of $24.50. The stock’s 50-day moving average is $18.94 and its 200-day moving average is $18.94. The company’s market cap is $400.1 million.

T2 Biosystems, Inc is an in vitro diagnostics company. The Company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies.

The Fly On The Wall

Receive News & Ratings for T2 Biosystems Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.